News | May 10, 2012

Post-PASSION Trial Finds Long-Term Outcome Similar With Thrombus Aspiration and Stents in PCI


May 10, 2012 — New research confirms thrombus aspiration (TA) during percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI) provides long-term outcomes similar to conventional intervention with bare-metal or drug-eluting stents. Findings published in a special STEMI-focused issue of Catheterization and Cardiovascular Interventions, the journal of the Society for Cardiovascular Angiography and Interventions (SCAI), report that compared to conventional PCI, thrombectomy does not affect rates of major adverse cardiac events at two-year follow up.

The World Health Organization (WHO) reports that cardiovascular diseases are the number one cause of death worldwide, and by 2030 nearly 24 million people will die primarily from heart disease and stroke. PCI, known also as angioplasty, is used to open blocked arteries to restore blood flow, and more than one million Americans have this procedure each year, according to the National Heart, Lung, and Blood Institute.

For the current study, Maarten Vink and colleagues in the Netherlands analyzed data from the PASSION trial to evaluate long-term outcomes with TA versus standard PCI with stents. As part of the trial, 619 STEMI patients were randomized to paclitaxel-eluting or bare-metal stents, with TA performed in just more than half of participants (311). Long-term outcomes, including cardiac death, recurrent myocardial infarction (MI) or target-lesion revascularization (TLR), were compared between patients undergoing TA compared to conventional PCI.

Two-year follow-up was completed for 598 patients. Cumulative incidence of cardiac death, recurrent MI and TLR was found in 13 percent of TA patients and 13.5 percent of participants in the conventional PCI group. TLR incidence was comparable in the TA and standard PCI groups at 7.7 percent and 8.3 percent, respectively. Researchers did not observe a significant difference in adverse cardiac events between the groups.

“Our post-hoc analysis of the PASSION trial found that TA in conjunction with PCI did not affect the incidence of adverse cardiac events at the two-year follow-up compared to conventional PCI,” concluded Vink “We observed no difference in stent thrombosis between the two groups.”

For more information: www.scai.org/asset.axd?id=88a5a9ca-e8d2-4bac-8ee2-b7eccade0844&t=634715447862530000


Related Content

News | Cardiovascular Clinical Studies

May 2, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...

Home May 02, 2024
Home
News | Cardiovascular Clinical Studies

May 1, 2024 — A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is ...

Home May 01, 2024
Home
News | Cardiovascular Clinical Studies

April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart ...

Home April 30, 2024
Home
News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
Subscribe Now